Camzyos (mavacamten) presentations include real-world outcomes from COLLIGO-HCM and a pooled monotherapy analysis from four Phase 3 studies
Results add to growing body of evidence supporting the efficacy and safety profile of this first and only approved cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain. Data to be presented at the meeting include new real-world analyses of Camzyos (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) as well as data on behalf of the BMS-Pfizer Alliance on Eliquis (apixaban).
“With a 70-year legacy in cardiovascular medicine, we are deeply committed to advancing life-changing therapies for patients, including those living with symptomatic obstructive HCM,” said Roland Chen, MD, senior vice president, drug development, Immunology and Cardiovascular Medicines, Bristol Myers Squibb. “Camzyos is the first and only available cardiac myosin inhibitor supported by robust long-term extension and real-world effectiveness data in patients with oHCM, with clinical studies demonstrating symptom relief as well as improvements in functional capacity and cardiac structure, both with and without background therapy. We look forward to sharing new data at this year’s ESC Congress building on our growing body of real-world evidence that reinforce its overall safety profile and benefits for diverse patients around the world.”
Key presentations include:
An oral presentation showing real-world outcomes for Camzyos for the treatment of symptomatic oHCM from COLLIGO-HCM, a global observational study reflecting diverse patient populations in five countries (the United States, Canada, the United Kingdom, Australia, and Israel).
An oral presentation spotlighting the efficacy and safety of Camzyos monotherapy in treating patients with oHCM based on a pooled analysis of four Phase 3 studies.
A late-breaking oral presentation highlighting topline results from ODYSSEY-HCM, a Phase 3 randomized, double-blind, placebo-controlled trial in 580 adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy (nHCM), the largest and longest-duration study completed to date in this patient population.
Select abstracts sponsored by Bristol Myers Squibb and the BMS-Pfizer Alliance to be presented at ESC Congress 2025 can be found below. Complete abstracts may be accessed online here. Visit the following page on BMS.com for more information on Bristol Myers Squibb’s scientific approach to and resources on cardiovascular diseases.
About CAMZYOS® (mavacamten)
CAMZYOS® (mavacamten) is the first and only cardiac myosin inhibitor approved in the U.S., indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms, and in the European Union, indicated for the treatment of symptomatic (NYHA, class II-III) oHCM in adult patients. It has also received regulatory approvals in more than 50 countries and regions across five continents. CAMZYOS is a selective, reversible, allosteric inhibitor of cardiac myosin. CAMZYOS modulates the number of myosin heads that can enter “on actin” (power-generating) states, thus reducing the probability of force-producing (systolic) and residual (diastolic) cross-bridge formation. Excess myosin actin cross-bridge formation and dysregulation of the super-relaxed state are mechanistic hallmarks of HCM. CAMZYOS shifts the overall myosin population towards an energy-sparing, recruitable, super-relaxed state. In oHCM patients, myosin inhibition with CAMZYOS reduces dynamic left ventricular outflow tract (LVOT) obstruction and improves cardiac filling pressures. These effects on the heart translate to improvement in symptoms and ability to be active in symptomatic patients with oHCM.
About ELIQUIS® (apixaban)
ELIQUIS® is an oral selective Factor Xa inhibitor. By inhibiting Factor Xa, a key blood clotting protein, ELIQUIS decreases thrombin generation and blood clot formation. ELIQUIS is approved for multiple indications in the U.S. based on efficacy and safety data from multiple Phase 3 clinical trials. ELIQUIS is a prescription medicine indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF); for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery; for the treatment of DVT and PE in adult patients, and to reduce the risk of recurrent DVT and PE following initial therapy. ELIQUIS is also indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. ELIQUIS continues to be developed and commercialized by The Bristol Myers Squibb-Pfizer Alliance.
About Bristol Myers Squibb
At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve.